Most US clinicians plan to prescribe Incivek and Victrelis for treatment-naive hep C patients
More than two-thirds of surveyed US clinicians plan to prescribe Vertex/Johnson & Johnson/Mitsubishi Tanabe’s Incivek (telaprevir) and Merck & Co/Roche’s Victrelis (boceprevir) to patients with treatment-naive hepatitis C virus genotype 1 (HCV1), and half of them indicated they will add Incivek or Victrelis to an HCV1 patient’s existing pegylated-interferon (peg-IFN)/ribavirin regimen, according to a news report from health care advisory firm Decision Resources.
Incivek and Victrelis were recently approved as treatments for hepatitis C virus by the US Food and Drug Administration (The Pharma Letter May 16 and 24). As previously reported by TPL, the two new hepatitis C drugs will vie for share of a US market valued at $4 billion, of which Incivek has been forecast to bag the biggest (70%-80%) share, although Merck’s tie-up with sector rival Roche (TPL May 18) could result in a stronger marketing effort than that first expected.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze